These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8490694)

  • 41. Cephalosporin therapeutics for intensive care infections.
    Salacata A; Chow JW
    New Horiz; 1993 May; 1(2):181-6. PubMed ID: 7922401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapies directed against endotoxin--has the time come?
    Quezado ZM; Hoffman WD
    West J Med; 1993 Apr; 158(4):424-5. PubMed ID: 8317138
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical trials of immunotherapy for sepsis.
    Cunnion RE
    Crit Care Med; 1992 Jun; 20(6):721-3. PubMed ID: 1597020
    [No Abstract]   [Full Text] [Related]  

  • 47. Morbidity and mortality of bloodstream infections in patients with severe burn injury.
    Brusselaers N; Monstrey S; Snoeij T; Vandijck D; Lizy C; Hoste E; Lauwaert S; Colpaert K; Vandekerckhove L; Vogelaers D; Blot S
    Am J Crit Care; 2010 Nov; 19(6):e81-7. PubMed ID: 21041189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
    Chalfin DB; Holbein ME; Fein AM; Carlon GC
    JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
    Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
    Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

  • 52. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
    Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.
    Safdar N; Handelsman J; Maki DG
    Lancet Infect Dis; 2004 Aug; 4(8):519-27. PubMed ID: 15288826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
    Teng CP; Chen HH; Chan J; Lye DC
    Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.
    Oliveira AL; de Souza M; Carvalho-Dias VM; Ruiz MA; Silla L; Tanaka PY; Simões BP; Trabasso P; Seber A; Lotfi CJ; Zanichelli MA; Araujo VR; Godoy C; Maiolino A; Urakawa P; Cunha CA; de Souza CA; Pasquini R; Nucci M
    Bone Marrow Transplant; 2007 Jun; 39(12):775-81. PubMed ID: 17438585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis.
    Johnson MT; Reichley R; Hoppe-Bauer J; Dunne WM; Micek S; Kollef M
    Crit Care Med; 2011 Aug; 39(8):1859-65. PubMed ID: 21499086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia.
    Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Hoppe-Bauer J; Dunne WM; Kollef MH
    J Hosp Med; 2011 Sep; 6(7):405-10. PubMed ID: 21916003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.
    Alves MD; Ribeiro VB; Tessari JP; Mattiello F; De Bacco G; Luz DI; Vieira FJ; Behle TF; Pasqualotto AC; Zavascki AP
    J Antimicrob Chemother; 2014 Jun; 69(6):1681-7. PubMed ID: 24474430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experiences of bacteremia caused by metallo-beta-lactamase-producing gram-negative organisms.
    Lee NY; Yan JJ; Lee HC; Liu KH; Huang ST; Ko WC
    J Microbiol Immunol Infect; 2004 Dec; 37(6):343-9. PubMed ID: 15599466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.